Aducanumab's developers stopped two studies earlier this year because it didn’t seem to be working, then did a stunning about-face in October and said new results suggest it was effective at a high dose.

A Queen's University study found that Alzheimer's patients have less of the hormone irisin, which has led them to create ways of boosting irisin in the brain.